Skip to main content
Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc. — Investor Relations & Filings

Ticker · TPST ISIN · US69014Q1013 US Professional, scientific and technical activities
Open in API
Filings indexed 985 across all filing types
Latest filing 2018-11-01 Delisting Announcement
Country US United States of America
Listing US TPST

About Tempest Therapeutics, Inc.

https://www.tempesttx.com/

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates and cell therapies. The company develops first-in-class therapeutics that combine tumor-targeted and immune-mediated mechanisms to treat cancer. Its lead product candidate is amezalpat (TPST-1120), an oral, selective PPARα antagonist being evaluated in a global, randomized combination study for hepatocellular carcinoma. In addition to its small molecule platform, the company is also developing dual-chimeric antigen receptor (CAR) T-cell programs.

Recent filings

Filing Released Lang Actions
8-K
Delisting Announcement Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The content includes announcements about a Second Amendment to a Merger Agreement, a Stock Purchase Agreement, a Registration Rights Agreement, and a Notice of Delisting or Transfer of Listing from Nasdaq Global Market to Nasdaq Capital Market. The document does not contain full financial statements or detailed financial performance data but rather reports on material definitive agreements, financing arrangements, and listing status updates. The presence of a delisting notice and transfer of listing is a key indicator. Therefore, the document is best classified as a Delisting Announcement (DLST). The document length is substantial (15,000 characters), and it contains detailed information about the delisting and related agreements, not just a brief announcement or a report publication notice. Hence, it is not an RPA or RNS. Confidence is high due to the clear presence of delisting-related content and merger/financing updates within a Form 8-K.
2018-11-01 English
425 Filing
Regulatory Filings
2018-11-01 English
SC 13G
Major Shareholding Notification
2018-10-26 English
FORM 4 -
Director's Dealing
2018-10-03 English
FORM 4 -
Director's Dealing
2018-10-03 English
FORM 4 -
Director's Dealing
2018-10-03 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.